Incretin Atlas › Trials › Zenagamtide s.c. phase 2 (T2D)
Zenagamtide s.c. phase 2 (T2D)
Amycretin · t2d
Design
- Molecule(s)
- Amycretin
- Population
- t2d
- Phase
- 2
- Participants
- 38
- Duration
- 36 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| zenagamtide 10 mg weekly | t2d | 36 | 38 | −12.9 % vs −2.1 % Δ −10.8 pp | — | −1.4 vs −0.1 | 21.0 vs 6.0 | — | 26.0 vs 14.0 | 11.0 vs 6.0 | 13.0 vs 8.0 | −9.4 vs −3.5 | verified |
| zenagamtide 20 mg weekly | t2d | 36 | 38 | −13.1 % vs −2.1 % Δ −11.0 pp | — | −1.6 vs −0.1 | 34.0 vs 6.0 | 45.0 vs 14.0 | 50.0 vs 14.0 | 24.0 vs 6.0 | 8.0 vs 8.0 | −7.2 vs −3.5 | verified |
| zenagamtide 40 mg weekly | t2d | 36 | 38 | −14.6 % vs −2.1 % Δ −12.5 pp | — | −1.7 vs −0.1 | 34.0 vs 6.0 | 45.0 vs 14.0 | 37.0 vs 14.0 | 29.0 vs 6.0 | 3.0 vs 8.0 | −10.6 vs −3.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (23)
- zenagamtide 10 mg weekly · weight_eff · Table 2, Bodyweight change, % row
−4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
- zenagamtide 10 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 10 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 10 mg weekly · vomiting · Table 3
Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
- zenagamtide 10 mg weekly · sae · Results, adverse events paragraph; Table 3
five (13%) in the 10 mg group
- zenagamtide 10 mg weekly · hba1c · Table 2
Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
- zenagamtide 10 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
- zenagamtide 20 mg weekly · weight_eff · Table 2, Bodyweight change, % row
−4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
- zenagamtide 20 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 20 mg weekly · disc_any · Results, paragraph 2
17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
- zenagamtide 20 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 20 mg weekly · vomiting · Table 3
Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
- zenagamtide 20 mg weekly · sae · Results, adverse events paragraph; Table 3
three (8%) in the 20 mg group
- zenagamtide 20 mg weekly · hba1c · Table 2
Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
- zenagamtide 20 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
- zenagamtide 40 mg weekly · weight_eff · Results, paragraph 7; Table 2
to −14·6% with zenagamtide 40 mg (−12·5% [−16·79 to −8·21]; p<0·0001), compared with −2·1% with placebo
- zenagamtide 40 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 40 mg weekly · disc_any · Results, paragraph 2
17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
- zenagamtide 40 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 40 mg weekly · vomiting · Results, adverse events paragraph; Table 3
vomiting in one (3%) of 38 participants in the 0·4 mg group and 11 (29%) of 38 participants in the 40 mg group
- zenagamtide 40 mg weekly · sae · Results, adverse events paragraph; Table 3
one (3%) in the 40 mg group
- zenagamtide 40 mg weekly · hba1c · Results, paragraph 3; Table 2
to −1·7% with zenagamtide 40 mg (−1·56% [−2·05 to −1·07]; p<0·0001; table 2)
- zenagamtide 40 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Zenagamtide s.c. phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/zenagamtide-s-c-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.